Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity
- PMID: 14632309
- DOI: 10.1002/bdra.10081
Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity
Abstract
Background: Like angiotensin converting enzyme (ACE) inhibitors angiotensin II (AT II)-receptor-antagonists may cause persistent or even lethal fetotoxic defects when used during the late second or third trimester. There are insufficient data on first-trimester exposure to these substances in terms of teratogenicity. The two databases of the Berlin Teratology Information Service (TIS) were evaluated for pregnancy outcome following exposure to AT II-receptor-antagonists. One database covers case reports on newborns with congenital abnormalities identified after birth, in which drug-effect associations can be evaluated retrospectively. The other enrolls women prospectively according to exposure to particular drugs during pregnancy, with follow-up of pregnancy outcome.
Cases: Five cases (four retrospective and one prospective) involving late-pregnancy use of AT II-receptor-antagonists were recently reported to us, each of which included one or more of the following abnormalities: oligohydramnios/anhydramnios, anuria, hypoplastic skull bones, limb contractions, lung hypoplasia, and neonatal death. Among 37 prospectively enrolled first-trimester-exposed pregnancies there were 30 live births including one with a major malformation (cleft palate). One pregnancy was electively terminated after exencephaly had been diagnosed.
Conclusions: AT II-receptor-antagonists may induce fetotoxic effects when used in the second and third trimesters. The available data on first-trimester use do not strongly support a teratogenic potential. AT II-receptor-antagonists should not be used by pregnant women. In case of inadvertent exposure, therapy should be changed to the known antihypertensives of choice (e.g., metoprolol, methyldopa, and hydralazine) and fetotoxic effects should be ruled out by ultrasound. Treatment with AT II-receptor-antagonists during early pregnancy is not in itself an indication for termination of a wanted pregnancy.
Similar articles
-
[Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].Ugeskr Laeger. 1998 Mar 2;160(10):1460-4. Ugeskr Laeger. 1998. PMID: 9520613 Review. Danish.
-
Clinical implications of increased congenital malformations after first trimester exposures to angiotensin-converting enzyme inhibitors.J Cardiovasc Nurs. 2008 Jan-Feb;23(1):20-4. doi: 10.1097/01.JCN.0000305052.73376.de. J Cardiovasc Nurs. 2008. PMID: 18158502
-
Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.Early Hum Dev. 2006 Jan;82(1):23-8. doi: 10.1016/j.earlhumdev.2005.11.001. Epub 2006 Jan 19. Early Hum Dev. 2006. PMID: 16427219 Review.
-
Angiotensin II receptor antagonist treatment during pregnancy.Birth Defects Res A Clin Mol Teratol. 2005 Feb;73(2):123-30. doi: 10.1002/bdra.20102. Birth Defects Res A Clin Mol Teratol. 2005. PMID: 15669052 Review.
-
Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors.Obstet Gynecol. 1992 Sep;80(3 Pt 1):429-32. Obstet Gynecol. 1992. PMID: 1495700
Cited by
-
What Do We Know about Peripartum Cardiomyopathy? Yesterday, Today, Tomorrow.Int J Mol Sci. 2024 Sep 30;25(19):10559. doi: 10.3390/ijms251910559. Int J Mol Sci. 2024. PMID: 39408885 Free PMC article. Review.
-
Renin-angiotensin system in ureteric bud branching morphogenesis: implications for kidney disease.Pediatr Nephrol. 2014 Apr;29(4):609-20. doi: 10.1007/s00467-013-2616-3. Epub 2013 Sep 7. Pediatr Nephrol. 2014. PMID: 24061643 Review.
-
Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.J Renin Angiotensin Aldosterone Syst. 2018 Oct-Dec;19(4):1470320318810940. doi: 10.1177/1470320318810940. J Renin Angiotensin Aldosterone Syst. 2018. PMID: 30394825 Free PMC article.
-
(Pro)renin Receptor in Kidney Development and Disease.Int J Nephrol. 2011;2011:247048. doi: 10.4061/2011/247048. Epub 2011 Jun 20. Int J Nephrol. 2011. PMID: 21755055 Free PMC article.
-
A new role for the renin-angiotensin system in the development of the ureteric bud and renal collecting system.Keio J Med. 2008 Dec;57(4):184-9. doi: 10.2302/kjm.57.184. Keio J Med. 2008. PMID: 19110530 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous